Myoteri Despoina, Dellaportas Dionysios, Gklavas Antonios, Theodosopoulos Theodosios, Vassiliou Ioannis, Kondi-Pafiti Agatha, Konstantoulakis Manousos M, Contis John
Chirurgia (Bucur). 2020 Jul-Aug;115(4):441-447. doi: 10.21614/chirurgia.115.4.441.
Receptor-binding cancer antigen (RCAS1) is a membrane protein, regarded as a tumor-associated antigen. Cancer cells evade immune response with RCAS1 up-regulation, inducing apoptosis to tumor infiltrating lymphocytes. Thyroid cancer incidence is rising and its accurate diagnosis in early stage is targeted. The aim of this study is to access RCAS1 expression in benign and malignant thyroid pathology. This is a retrospective study of 110 patients, who had thyroidectomy in a single tertiary referral centre between January 2008 until December 2014. Immunohistochemistry study for RCAS1 expression was carried out and correlation with clinical and histopathological data is attempted. RCAS1 immunostaining was found positive in 81 out of 110 cases. Notably it was deemed positive in all malignant thyroid tissue samples (p 0.001). In thyroid malignancy, tumor size, thyroid capsule invasion and positive lymph nodes status were positively correlated with moderate and strong expression of RCAS1. For papillary thyroid carcinoma, the vast majority (35/37 cases, 94.6%) were also classified as having moderate or strong RCAS1 expression. RCAS1 expression can aid in differential diagnosis between benign and malignant thyroid pathology, while its strong expression correlates with worse oncological features.
受体结合癌抗原（RCAS1）是一种膜蛋白，被视为肿瘤相关抗原。癌细胞通过上调RCAS1逃避免疫反应，诱导肿瘤浸润淋巴细胞凋亡。甲状腺癌发病率呈上升趋势，其早期准确诊断是目标。本研究的目的是评估RCAS1在甲状腺良恶性病变中的表达。这是一项对110例患者的回顾性研究，这些患者于2008年1月至2014年12月在一家单一的三级转诊中心接受了甲状腺切除术。对RCAS1表达进行了免疫组织化学研究，并尝试将其与临床和组织病理学数据进行关联。在110例病例中，81例RCAS1免疫染色呈阳性。值得注意的是，在所有甲状腺恶性组织样本中均被视为阳性（p<0.001）。在甲状腺恶性肿瘤中，肿瘤大小、甲状腺包膜侵犯和阳性淋巴结状态与RCAS1的中度和强表达呈正相关。对于乳头状甲状腺癌，绝大多数（35/37例，94.6%）也被归类为具有中度或强RCAS1表达。RCAS1表达有助于甲状腺良恶性病变的鉴别诊断，而其强表达与更差的肿瘤学特征相关。
